ADPT · Adaptive Biotechnologies Corporation
Price
Snapshot
50 fields · last close| Market Cap | $4.26B |
| P/E | — |
| Float | 156.1M |
| Beta | 2.17 |
| Volatility 30D | 63.6% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | 62.7 |
| Price | 25.88 |
| Change | −3.11% |
| Prev Close | 26.71 |
| Open | 26.42 |
| Day Low | 25.19 |
| Day High | 26.88 |
| Avg Vol | 2 |
| Avg $ Vol | $55.06M |
| 52W High | 30.74 |
| 52W Low | 12.00 |
| 52W Pos | 74.1% |
| From High | −15.81% |
| From Low | +115.67% |
| Max DD 1Y | −39.35% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.13% |
| SMA 50 | −1.87% |
| SMA 200 | +31.20% |
| RSI (14) | 51.9 |
| Vol 90D | 55.3% |
| Vol 1Y | 67.1% |
| 1Y Range | 12–31 |
| Daily bars | 900 |
| Perf Week | −5.85% |
| Perf Month | −0.71% |
| Perf Quarter | +13.18% |
| Perf Half Y | +85.10% |
| Perf Year | +54.04% |
| Perf YTD | +62.66% |
| Prev Day | −3.11% |
| Clavix | C+ |
| Debt / Eq | 0.60 |
| Curr Ratio | 3.34 |
| Int Cover | -21.9× |
| FCF Margin | −17.7% |
| Rev Growth | +54.8% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 16 / 19 |
Clavix risk grade
regraded every trading dayADPT grades C+, 62.7 of 100. Steadiest on News Sentiment (67), most exposed on Price Stability (45, fragile). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 16 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| ADPT | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.17 | 1.16 |
| 30-day realized volatilityannualized, from daily closes | 63.6% | 30.3% |
| Max drawdown, past yearworst peak-to-trough fall | −39.3% | — |
| Typical daily movemedian absolute daily change | 2.08% | — |
| Days beyond ±3%of the last 252 sessions | 94 (37%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ADPT | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.17 | 1.16 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Moderate 53% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ADPT | |
|---|---|
| 1 week | −5.9% |
| 1 month | −0.7% |
| Year to date | +62.7% |
| 1 year | +54.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ADPT | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 24 Jul |
| Average score0 most bearish, 100 most bullish | 60 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 5 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| ADPT | |
|---|---|
| Revenue growthyear over year | +54.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAdaptive Biotechnologies reported quarterly earnings of $0.02 per share, beating the consensus estimate of a $0.10 loss and improving from a $0.15 loss a year earlier. The headline says revenue also exceeded estimates, but the article provides no revenue amount.
Adaptive Biotechnologies reported third-quarter 2026 revenue of $83.9 million, adjusted EBITDA of $14.3 million and free cash flow, cash left after operating spending and capital purchases, of $7.7 million. Minimal residual disease (MRD) revenue rose 28% year over year, or 44% excluding milestone payments, while clonoSEQ tests increased 46% to 39,587; management said performance supported another increase in its full-year outlook.
On October 28, Adaptive Biotechnologies COO Julie Rubinstein sold 11,881 shares at an average price of $28.45, totaling $338,014.45. The sale reduced her direct ownership by 3.05% to 377,802 shares, valued at $10,748,466.90, and was made under a pre-arranged trading plan.
New National Comprehensive Cancer Network guidelines and International Myeloma Society cure definitions are positioning Adaptive Biotechnologies' clonoSEQ as the standard for long-term monitoring of measurable residual disease in myeloma. MRD revenue grew 33% year over year to $66.2 million, clinical average selling prices rose 7%, test volumes rose 43%, and adjusted EBITDA margin reached 14%; ADPT also eliminated OrbiMed's revenue share and refinanced $345 million of zero-coupon notes, providing more than five years of cash runway.
Eight research firms covering Adaptive Biotechnologies (ADPT) have given the company an average 'Moderate Buy' rating, with a combined average price target of $28.94. The breakdown is six buy ratings, one hold, and one sell.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| TXG | 10x Genomics, Inc. | D+ | $8.51B | — | 2.07 | Compare |
| BRKR | Bruker Corporation | C+ | $9.72B | — | 1.26 | Compare |
| QGEN | QIAGEN N.V. | B+ | $10.50B | 25.58 | 0.57 | Compare |
| AVTR | Avantor, Inc. | B- | $10.60B | — | 0.95 | Compare |
| RGEN | Repligen Corporation | B- | $11.39B | 232.35 | 1.17 | Compare |
| TECH | Bio-Techne Corporation | A | $11.42B | 62.75 | 1.26 | Compare |
| TEM | Tempus AI, Inc. | D- | $13.79B | — | 2.50 | Compare |
| CRL | Charles River Laboratories International, Inc. | B- | $15.58B | — | 1.34 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.